IL92495A - Medicinal product containing recombinant human alpha interphone for the treatment of LLEC SUOMAUQS carcinoma in dose into the tumor - Google Patents

Medicinal product containing recombinant human alpha interphone for the treatment of LLEC SUOMAUQS carcinoma in dose into the tumor

Info

Publication number
IL92495A
IL92495A IL9249589A IL9249589A IL92495A IL 92495 A IL92495 A IL 92495A IL 9249589 A IL9249589 A IL 9249589A IL 9249589 A IL9249589 A IL 9249589A IL 92495 A IL92495 A IL 92495A
Authority
IL
Israel
Prior art keywords
interferon
squamous cell
cell carcinoma
treatment
intralesionally
Prior art date
Application number
IL9249589A
Other languages
English (en)
Hebrew (he)
Other versions
IL92495A0 (en
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of IL92495A0 publication Critical patent/IL92495A0/xx
Publication of IL92495A publication Critical patent/IL92495A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL9249589A 1988-12-01 1989-11-29 Medicinal product containing recombinant human alpha interphone for the treatment of LLEC SUOMAUQS carcinoma in dose into the tumor IL92495A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US27831588A 1988-12-01 1988-12-01

Publications (2)

Publication Number Publication Date
IL92495A0 IL92495A0 (en) 1990-08-31
IL92495A true IL92495A (en) 1995-05-26

Family

ID=23064525

Family Applications (1)

Application Number Title Priority Date Filing Date
IL9249589A IL92495A (en) 1988-12-01 1989-11-29 Medicinal product containing recombinant human alpha interphone for the treatment of LLEC SUOMAUQS carcinoma in dose into the tumor

Country Status (14)

Country Link
EP (2) EP0372809B1 (ja)
JP (1) JPH0647556B2 (ja)
KR (1) KR950011889B1 (ja)
AT (1) ATE92333T1 (ja)
AU (1) AU634511B2 (ja)
CA (1) CA2004202C (ja)
DE (1) DE68908119T2 (ja)
DK (1) DK103891D0 (ja)
ES (1) ES2058555T3 (ja)
IE (1) IE63121B1 (ja)
IL (1) IL92495A (ja)
MY (1) MY107071A (ja)
WO (1) WO1990006135A1 (ja)
ZA (1) ZA899113B (ja)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2098393A1 (en) * 1990-12-14 1992-06-15 Robert J. Spiegel Oral administration of alpha interferon to treat lung malignancies
PT99837A (pt) * 1990-12-21 1992-12-31 Schering Corp Processo para a preparacao de composicoes farmaceuticas contendo interferao alfa e metodo para administracao de interferao alfa por inalacao oral para tratar asma e doencas pulmonares proliferativas nao malignas
US7294332B2 (en) 1995-10-04 2007-11-13 Schering Corporation Combination therapy (temozolomide and α-IFN) for advanced cancer
ES2183977T3 (es) * 1995-10-04 2003-04-01 Schering Corp Combinacion de temozolomida y alfa-interferon para el tratamiento de cancer avanzado.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3278234D1 (en) * 1981-10-13 1988-04-21 Exovir Inc Interferon-containing compositions and the use of these compositions in the treatment of herpetic infections, pre-malignant skin lesions, skin malignancies and psoriasis
IE62318B1 (en) * 1986-05-27 1995-01-25 Schering Corp Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon

Also Published As

Publication number Publication date
IE63121B1 (en) 1995-03-22
DK103891A (da) 1991-05-31
IL92495A0 (en) 1990-08-31
DE68908119D1 (de) 1993-09-09
ZA899113B (en) 1990-08-29
DE68908119T2 (de) 1993-11-18
DK103891D0 (da) 1991-05-31
AU634511B2 (en) 1993-02-25
JPH04500678A (ja) 1992-02-06
KR950011889B1 (ko) 1995-10-12
ATE92333T1 (de) 1993-08-15
MY107071A (en) 1995-09-30
EP0372809A1 (en) 1990-06-13
EP0446279A1 (en) 1991-09-18
WO1990006135A1 (en) 1990-06-14
KR900701311A (ko) 1990-12-01
CA2004202A1 (en) 1990-06-01
ES2058555T3 (es) 1994-11-01
AU4802590A (en) 1990-06-26
IE893828L (en) 1990-06-01
CA2004202C (en) 2001-02-13
EP0372809B1 (en) 1993-08-04
JPH0647556B2 (ja) 1994-06-22

Similar Documents

Publication Publication Date Title
Wickramasinghe et al. Treatment of neoplastic skin lesions with intralesional interferon
US5028422A (en) Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon
US5256410A (en) Treatment of squamous cell carcinoma intralesionally with recombinant human alpha interferon
IE64765B1 (en) Use of cytokines
Edwards et al. Effect of intralesional a2-interferon on actinic keratoses
US5480640A (en) Alpha interferon for treating prostate cancer
Bernard et al. Transient focal neurologic deficits complicating interleukin‐2 therapy
US5002764A (en) Treatment of actinic keratoses with alpha2 interferon
AU634511B2 (en) Treatment of squamous cell carcinoma intralesionally with recombinant human alpha interferon
US4806347A (en) Interferon combinations
Doǧan et al. Intralesional alfa-2a interferon therapy for basal cell carcinoma
Brunda et al. The anti‐tumor effect of recombinant interferon alpha or gamma is influenced by tumor location
EP0248583B1 (en) Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon
Bleeker Intralesional triamcinolone acetonide using the Port‐O‐Jet and needle injections in localized dermatoses
Ikić et al. Interferon reduces recurrences of basal cell and squamous cell cancers
EP0369632A1 (en) Treatment of genital warts with a combination of liquid nitrogen and recombinant DNA human alpha interferon
Hussein Interleukin 1 protects against 1-β-D-arabinofuranosylcytosine-induced alopecia in the newborn rat animal model
Brody Electrical Activity in Sympathetic Nerves of Immunologically Sympathectomized Rats.
Shuttleworth et al. A comparison of the effects of intralesional interferon α-2b and topical 5% 5-fluorouracil cream in the treatment of solar keratoses and Bowen's disease
Lee et al. Clinical trials of interferon-gamma in treating warts
Jackson Treatment of superficial epitheliomatosis with an ointment containing demecolcin
Tsukuda et al. Clinical efficacy of recombinant human granulocyte colony-stimulating factor in patients with head and neck cancer
Cho et al. Basal Cell Carcinoma and Actinic Keratosis Treated with Intralesional Injection of Recombinant Alpha-2 Interferon
von Wussow INTRALESIONAL INTERFERON-ALPHA-THERAPY IN ADVANCED MALIGNANT MELANOMA Peter von Wussow Dept. of Clinical Immunology, Medical School of Hannover, Hannover, West-Germany
Cho et al. Intralesional Injection of Recombinant Alpha-2 Interferon

Legal Events

Date Code Title Description
RH Patent void